Physician profile
Julia Larson
NPI 1437635240
$9,998.30
in general payments reported to CMS, 2019-2025
27 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,624 · 2020: $195 · 2021: $696 · 2022: $1,325 · 2023: $1,614 · 2024: $979 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,158.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,360.92 | 2019-2022 | |
| Alcon Vision LLC | $1,918.09 | 2019-2025 | Hydrus Microstent, Rocklatan, Precision 1 |
| Bausch & Lomb Americas INC. | $1,025.95 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Dompe US, INC. | $594.65 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $584.96 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $394.27 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $325.61 | 2020-2024 | Misight Contact Lens, Myday Contact Lens, Onefit Contact Lens |
| Sun Pharmaceutical Industries INC. | $321.25 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $305.26 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $290.31 | 2021-2024 | Acthar |
| Johnson & Johnson Vision Care, INC. | $264.01 | 2019-2025 | Acuvue |
| Abbvie INC. | $256.20 | 2022-2025 | |
| Glaukos Corporation | $194.75 | 2022-2023 | Photrexa Cross-Linking Kit |
| Kala Pharmaceuticals, INC. | $189.43 | 2021-2022 | |
| Rxsight INC | $133.02 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $132.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $127.22 | 2022-2023 | |
| Biotissue Holdings INC. | $98.52 | 2020-2023 | |
| Shire North American Group INC | $97.25 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.38 | 2020 | |
| Eyevance Pharmaceuticals LLC | $83.60 | 2022-2023 | Flarex |
| Ocular Therapeutix, INC. | $72.97 | 2023-2025 | Dextenza |
| Thea Pharma INC. | $39.50 | 2023 | |
| Optos, INC. | $35.38 | 2022 | |
| Allergan, INC. | $23.90 | 2022 | |
| Abb Con-Cise Optical Group LLC | $18.32 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.